A Phase 1 Dose-escalation Study of UGN-501 Administered Intravesically in Adult Participants With Recurrent NMIBC

Clinical trial NCT07725796 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07725796
Sponsor: UroGen Pharma, Inc., a subsidiary of UroGen Pharma Ltd.
Status: NOT_YET_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Bladder (Urothelial, Transitional Cell) Cancer NMIBC Urothelial Carcinoma Bladder Urothelial Carcinoma in Situ Urothelial Carcinoma Recurrent Urothelial Carcinoma of the Urinary Bladder Non-Muscle Invasive Bladder Carcinoma Non-muscle Invasive Bladder Cancer (NMIBC)

Start date: 2026-09-30
Primary completion: 2029-08-02
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.